stoxline Quote Chart Rank Option Currency Glossary
Tenaya Therapeutics, Inc. (TNYA)
3.76  0.09 (2.45%)    07-23 16:00
Open: 3.65
High: 3.8099
Volume: 237,085
Pre. Close: 3.67
Low: 3.63
Market Cap: 295(M)
Technical analysis
2024-07-23 4:55:41 PM
Short term     
Mid term     
Targets 6-month :  4.46 1-year :  5.21
Resists First :  3.81 Second :  4.46
Pivot price 3.33
Supports First :  3.05 Second :  2.57
MAs MA(5) :  3.56 MA(20) :  3.25
MA(100) :  4.28 MA(250) :  3.67
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  79.2 D(3) :  71.6
RSI RSI(14): 58.1
52-week High :  7.01 Low :  1.65
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TNYA ] has closed below upper band by 16.3%. Bollinger Bands are 6.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.82 - 3.83 3.83 - 3.85
Low: 3.59 - 3.61 3.61 - 3.62
Close: 3.73 - 3.76 3.76 - 3.79
Company Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Headline News

Mon, 22 Jul 2024
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Rating of “Buy” from Analysts - Defense World

Thu, 27 Jun 2024
Tenaya Therapeutics Announces Research Leadership Updates - Yahoo Finance

Tue, 18 Jun 2024
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit - GlobeNewswire

Mon, 10 Jun 2024
William Blair starts Tenaya Therapeutics stock with Outperform rating -

Tue, 04 Jun 2024
We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate - Simply Wall St

Sat, 25 May 2024
We're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 79 (M)
Shares Float 56 (M)
Held by Insiders 1.1 (%)
Held by Institutions 71.8 (%)
Shares Short 3,890 (K)
Shares Short P.Month 3,440 (K)
Stock Financials
EPS -1.65
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.01
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -38.2 %
Return on Equity (ttm) -66.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.57
Qtrly Earnings Growth 0 %
Operating Cash Flow -100 (M)
Levered Free Cash Flow -59 (M)
Stock Valuations
PE Ratio -2.28
PEG Ratio 0
Price to Book value 1.86
Price to Sales 0
Price to Cash Flow -2.94
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android